亚太药业(002370) - 2024 Q2 - 季度业绩预告

Financial Performance - Net profit attributable to shareholders of the listed company is expected to be between 4.5 million yuan and 6.5 million yuan, a year-on-year decrease of 67.12% to 77.23%[2] - Revenue is expected to be between 220 million yuan and 230 million yuan, compared to 221.14 million yuan in the same period last year[2] - Basic earnings per share are expected to be between 0.0074 yuan and 0.0107 yuan, compared to 0.04 yuan in the same period last year[2] Factors Affecting Net Profit - The decrease in net profit is mainly due to the reversal of previously accrued estimated liabilities of 51.79 million yuan related to the Wuhan Rural Commercial Bank case and investor litigation[6] - Excluding non-recurring gains and losses, the net profit after deducting non-recurring gains and losses is expected to reduce losses by 73.99% to 79.90% year-on-year, mainly due to reduced interest on convertible bonds and lower sales expenses[16] Non-Recurring Gains - The company received a remaining property distribution of 2,766,105.25 CAD (approximately 14.46 million yuan) from the joint venture YATAI & BBT Biotech Ltd., which increased the total profit for the first half of 2024[9]